|
|
 |
|
Total Number of Holdings (excluding cash): 30
| Intra-Cellular Therapies, Inc. |
ITCI |
46116X101 |
Health Care |
564,159 |
$41,753,407.59 |
3.78% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Health Care |
276,005 |
$38,665,540.45 |
3.50% |
| Moderna, Inc. |
MRNA |
60770K107 |
Health Care |
353,498 |
$38,138,899.22 |
3.45% |
| Amgen Inc. |
AMGN |
031162100 |
Health Care |
139,056 |
$38,037,378.24 |
3.44% |
| BioNTech SE (ADR) |
BNTX |
09075V102 |
Health Care |
429,774 |
$38,030,701.26 |
3.44% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Health Care |
1,629,409 |
$37,948,935.61 |
3.43% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Health Care |
93,725 |
$37,950,189.75 |
3.43% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Health Care |
962,622 |
$37,513,379.34 |
3.39% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Health Care |
159,795 |
$37,467,133.65 |
3.39% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Health Care |
41,082 |
$37,274,520.24 |
3.37% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Health Care |
403,023 |
$37,102,297.38 |
3.36% |
| Repligen Corporation |
RGEN |
759916109 |
Health Care |
216,678 |
$37,112,607.84 |
3.36% |
| Alkermes Plc |
ALKS |
G01767105 |
Health Care |
1,521,983 |
$36,923,307.58 |
3.34% |
| argenx SE (ADR) |
ARGX |
04016X101 |
Health Care |
98,320 |
$36,877,865.60 |
3.34% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Health Care |
250,282 |
$36,558,691.74 |
3.31% |
| BeiGene, Ltd. (ADR) |
BGNE |
07725L102 |
Health Care |
263,035 |
$36,559,234.65 |
3.31% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Health Care |
546,009 |
$36,598,983.27 |
3.31% |
| Mettler-Toledo International Inc. |
MTD |
592688105 |
Health Care |
29,472 |
$36,584,183.04 |
3.31% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Health Care |
2,168,426 |
$36,299,451.24 |
3.29% |
| Corcept Therapeutics Incorporated |
CORT |
218352102 |
Health Care |
1,580,894 |
$36,360,562.00 |
3.29% |
| Illumina, Inc. |
ILMN |
452327109 |
Health Care |
292,491 |
$36,403,429.86 |
3.29% |
| Biogen Inc. |
BIIB |
09062X103 |
Health Care |
187,541 |
$36,229,170.38 |
3.28% |
| Genmab A/S (ADR) |
GMAB |
372303206 |
Health Care |
1,270,226 |
$36,277,654.56 |
3.28% |
| Waters Corporation |
WAT |
941848103 |
Health Care |
115,189 |
$36,088,713.70 |
3.27% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Health Care |
2,441,972 |
$35,970,247.56 |
3.26% |
| Natera, Inc. |
NTRA |
632307104 |
Health Care |
393,425 |
$35,817,412.00 |
3.24% |
| Incyte Corporation |
INCY |
45337C102 |
Health Care |
690,192 |
$35,648,416.80 |
3.23% |
| Bruker Corporation |
BRKR |
116794108 |
Health Care |
424,376 |
$34,994,044.96 |
3.17% |
| Beam Therapeutics Inc. |
BEAM |
07373V105 |
Health Care |
1,433,352 |
$33,640,771.44 |
3.04% |
| Exact Sciences Corporation |
EXAS |
30063P105 |
Health Care |
520,981 |
$33,097,922.93 |
3.00% |
| US Dollar |
$USD |
|
Other |
1,072,288 |
$1,072,288.22 |
0.10% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|